AIVL2.410%
as of Oct 23
MDT
GrowthMEDTRONIC PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Close · 3M
+18.70%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals17
Win rate94% (16/17)
Avg buy return+2.65%
AIVL · Accumulation · 5d
weight 2.275% → 2.394% (+0.119 pp)·stock up 3.1% in the 30 days before
Oct 20·entry $94.63·now $95.41Fresh
+0.82%
since Oct 20
AIVL · Weight decrease · 2d
weight 2.433% → 2.372% (-0.061 pp)·stock up 0.7% in the 30 days before
Oct 19·entry $92.77·now $95.41
+2.85%
since Oct 19
AIVL · Accumulation · 5d
weight 2.230% → 2.417% (+0.188 pp)·stock up 2.1% in the 30 days before
Oct 16·entry $94.75·now $95.41Fresh
+0.70%
since Oct 16
AIVL · Accumulation · 5d
weight 2.260% → 2.433% (+0.173 pp)·stock up 3.1% in the 30 days before
Oct 15·entry $95.45·now $95.41Fresh
-0.04%
since Oct 15
AIVL · Weight increase · 3d
weight 2.275% → 2.424% (+0.149 pp)·stock up 0.5% in the 30 days before
Oct 14·entry $94.23·now $95.41Fresh
+1.25%
since Oct 14
AIVL · Weight increase · 2d
weight 2.275% → 2.383% (+0.108 pp)·stock down 0.8% in the 30 days before
Oct 13·entry $93.01·now $95.41Drifting
+2.58%
since Oct 13
AIVL · Weight decrease · 2d
weight 2.299% → 2.230% (-0.069 pp)·stock down 7.4% in the 30 days before
Oct 7·entry $85.51·now $95.41
+11.58%
since Oct 7
AIVL · Weight decrease · 4d
weight 3.369% → 2.270% (-1.098 pp)·stock down 6.3% in the 30 days before
Oct 2·entry $86.38·now $95.41
+10.45%
since Oct 2
AIVL · Weight decrease · 3d
weight 3.369% → 3.265% (-0.104 pp)·stock down 6.1% in the 30 days before
Oct 1·entry $86.44·now $95.41
+10.38%
since Oct 1
AIVL · Weight decrease · 2d
weight 3.369% → 3.267% (-0.102 pp)·stock down 4.8% in the 30 days before
Sep 30·entry $86.29·now $95.41
+10.57%
since Sep 30
AIVL · Weight increase · 2d
weight 3.312% → 3.369% (+0.057 pp)·stock down 0.5% in the 30 days before
Sep 28·entry $89.50·now $95.41Drifting
+6.60%
since Sep 28
AIVL · Weight decrease · 7d
weight 3.466% → 3.312% (-0.155 pp)·stock down 2.9% in the 30 days before
Sep 24·entry $88.51·now $95.41
+7.80%
since Sep 24
AIVL · Weight decrease · 6d
weight 3.466% → 3.322% (-0.145 pp)·stock down 3.9% in the 30 days before
Sep 23·entry $89.30·now $95.41
+6.84%
since Sep 23
AIVL · Weight decrease · 5d
weight 3.466% → 3.366% (-0.100 pp)·stock down 2.8% in the 30 days before
Sep 22·entry $90.77·now $95.41
+5.11%
since Sep 22
AIVL · Weight decrease · 4d
weight 3.466% → 3.395% (-0.072 pp)·stock down 0.6% in the 30 days before
Sep 21·entry $91.75·now $95.41
+3.99%
since Sep 21
AIVL · Weight decrease · 3d
weight 3.466% → 3.423% (-0.043 pp)·stock down 2.1% in the 30 days before
Sep 18·entry $92.13·now $95.41
+3.56%
since Sep 18
AIVL · Weight decrease · 2d
weight 3.466% → 3.436% (-0.030 pp)·stock up 0.7% in the 30 days before
Sep 17·entry $92.77·now $95.41
+2.85%
since Sep 17
AIVL · Accumulation · 5d
weight 3.355% → 3.466% (+0.111 pp)·stock up 2.7% in the 30 days before
Sep 15·entry $93.75·now $95.41Fresh
+1.77%
since Sep 15
AIVL · Accumulation · 5d
weight 3.351% → 3.455% (+0.104 pp)·stock up 3.6% in the 30 days before
Sep 14·entry $93.80·now $95.41Fresh
+1.72%
since Sep 14
+4.14%
since Sep 10
+3.83%
since Sep 9
+1.32%
since Sep 4
AIVL · Weight increase · 2d
stock up 6.2% in the 30 days before
Aug 31·entry $90.65·now $95.41Drifting
+5.25%
since Aug 31
+4.69%
since Aug 25
+2.70%
since Aug 24
+2.21%
since Aug 21
+1.36%
since Aug 19
+3.61%
since Aug 18
+5.31%
since Aug 17
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Sep 20
AI ETF AIVL has shown a mixed pattern of gradual accumulation followed by recent decreases in its weight for Medtronic, indicating a lack of strong conviction or ongoing re-evaluation. This contrasts with a Buffett-style framework's clear 'Fail' verdict, which would advise against investment due to significant concerns regarding financial health, despite the company's strong competitive position.
- Circle of CompetenceMedtronic's diversified portfolio in essential medical devices provides stable unit economics, allowing for reasonably predictable long-term cash flow projections within the circle of competence.
- Economic MoatThe company benefits from strong economic moats including high switching costs for integrated medical systems, regulatory barriers to entry, and a well-established brand reputation in healthcare.
- ManagementInformation on management's candor, capital allocation decisions, or skin in the game is not provided, preventing a judgment on this criterion.
- Financial HealthThe most recent Return on Equity of 10.61% is barely above the minimum threshold for a single year and makes it highly improbable the 10-year average ROE meets the stringent 15% target, indicating a likely failure in financial health.
- Margin of SafetyWithout an intrinsic value estimate or the components to calculate owner earnings, a defensible margin of safety cannot be assessed from the provided data.
Medtronic passes the initial tests for operating within a predictable circle of competence and possessing strong economic moats. However, the financial health criteria are not met, specifically due to a weak single-year ROE that makes it unlikely to satisfy the demanding 10-year average ROE target. This financial concern, coupled with the inability to assess management and a margin of safety due to data limitations, results in a 'Fail' verdict according to this framework.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.